Two publications in Nature report on advances from the Human Cell Atlas (HCA) consortium, creating the most comprehensive Cell Atlas of the gut to date, identifying new targets for gut diseases, and laying out a framework for expansion of the project to other parts of the anatomy.
CureDuchenne Link is powered by technology from BC Platforms, a global leader in healthcare data management, analytics, and access. The data warehouse uses BC|INSIGHT, a HIPAA-compliant translational research platform, which allows for automated ingestion and harmonization of clinical information and multiple data types including genomics and other omics data.
Managed through the Avera Cancer Institute, the deal with Sema4 will leverage the company’s Centrellis health information platform to curate, structure and integrate clinical and genomic data to support both cancer research and clinical care.
Spanish researchers have developed a tool, based on machine learning methods, that assesses the possible contribution of all variants in a gene in a given type of tumor to the development and progression of cancer.
In a boost for AI-aided biology, the AlphaFold Protein Structure Database, covering around 20,000 human proteins, was launched today by AI-specialists DeepMind in collaboration with the EMBL and is openly available to the scientific community.
Swiss big data firm Sophia Genetics partners with U.S. medtech giant GE Healthcare to use AI and big-data analytics to advance precision oncology.
Recent regulatory changes and the global pandemic have highlighted the need for exploring 'in-silico' trials, carried out on virtual populations, as a way to speed up and reduce costs of drug and medical device development, while still maintaining accuracy.
Known as Summix, the method adjusts information to match the ancestry of a person or sample of people with the goal of making large genetic databases more useful for people of traditionally underrepresented ancestries.
Gene dependency relationships, including synthetic lethality, may produce cancer ‘Achilles heels’; a Belfast-based team has designed a program to look for these vulnerabilities which was very effective at finding them in a range of different cancer cells and tissues.
The findings are a result of in-depth analyses using Centogene’s rare disease Bio/Databank. Based on the results, more than 90 patients finally received a diagnosis, and many others could also benefit as the study revealed potential treatment options for patients based on known-disease overlaps.